EGEN, Inc. was founded in 2002 to develop novel proprietary nanoparticle delivery technology for therapeutic use.
EGEN's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas™ and TheraSilence™ platforms to the treatment of human disease.
In addition, EGEN is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies.
EGEN is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications.